Semaglutide for Weight Loss: A Complete Evidence-Based Guide to GLP-1 Therapy

If you are reading this, you have probably heard the headlines: a once-weekly injection that helps patients lose 15 to 20 percent of their body weight. The drug is real, the results are real, and the science behind it is not new. Semaglutide has been studied in tens of thousands of patients across multiple randomized controlled trials [1] [2].

What is new is the willingness of physicians to prescribe it for weight management rather than just type 2 diabetes. This guide covers what semaglutide actually is, how it works in your body, what to expect on therapy, and the questions you should be asking your provider before starting.

What Is Semaglutide?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics a hormone your gut naturally releases after eating. That hormone signals your pancreas to release insulin, slows how fast your stomach empties, and tells your brain you are full. Semaglutide does the same thing, except it stays active in your bloodstream for about a week, instead of the few minutes natural GLP-1 lasts.

It was first approved by the FDA in 2017 for type 2 diabetes (under the brand name Ozempic) and then in 2021 specifically for chronic weight management (under the brand Wegovy) in adults with a BMI of 30 or higher, or 27 with at least one weight-related condition [3].

How Semaglutide Works for Weight Loss

The mechanism is multi-pronged, which is why it works when most weight loss drugs of the past did not:

• Appetite suppression in the brain. GLP-1 receptors in the hypothalamus reduce hunger signaling. Patients describe feeling satisfied with much smaller portions.
• Slowed gastric emptying. Food stays in your stomach longer, extending the feeling of fullness after meals.
• Better blood sugar control. Lower post-meal glucose spikes mean less of the insulin-driven hunger crash that causes snacking.
• Reduced food noise. This is the term patients use to describe the constant intrusive thoughts about food. Many report it quiets down within the first month.

Expected Results: What the Trials Actually Show

The pivotal STEP 1 trial randomized 1,961 adults with overweight or obesity (without diabetes) to weekly 2.4 mg semaglutide or placebo for 68 weeks. Both groups received lifestyle counseling [1].

Patients on semaglutide lost an average of 14.9% of their starting body weight, compared to 2.4% on placebo. Roughly one in three semaglutide patients lost 20% or more.

For context: a 200-pound person at 15% loss is down 30 pounds. At 20%, that is 40 pounds. These are results that bariatric surgery used to deliver.

Timeline of Results

• Weeks 1 to 4: Most patients notice reduced appetite and food cravings within 2 weeks. Weight loss is typically 2 to 5 pounds in the first month as the body adjusts.
• Months 2 to 3: Steady losses of 1 to 2 pounds per week. Dose escalation drives most of the appetite reduction in this window.
• Months 4 to 6: Average 10% body weight loss reached around month 5. Plateau periods are normal.
• Month 12+: Maximum response achieved between months 12 and 18 in most patients.

Dosing Protocol

Semaglutide for weight loss starts low and titrates up over four months. This is not because the drug needs ramping for efficacy. It is to minimize gastrointestinal side effects (nausea, mostly).

Some patients respond well at 1.0 mg or 1.7 mg and do not need to escalate to 2.4 mg. The goal is the lowest effective dose, not the highest tolerated dose.

Side Effects: The Honest List

Semaglutide is well-tolerated by most patients, but side effects do exist. The most common ones during the trials were [1]:

• Nausea (43%): Most common in the first 8 to 12 weeks. Usually mild and improves with dose adjustment, smaller meals, and avoiding high-fat foods.
• Diarrhea (30%): Often resolves with hydration and dietary modification.
• Constipation (24%): Counterintuitive but real. Slow gastric emptying affects the whole GI tract.
• Vomiting (24%): Less common after the first month.
• Fatigue (11%): Often related to undereating during the first weeks. Usually resolves once eating patterns stabilize.

Serious Side Effects (Rare but Important)

The FDA label includes a boxed warning for thyroid C-cell tumors, based on rodent studies. The relevance to humans is unclear, but semaglutide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome [3].

Pancreatitis has been reported, though large meta-analyses have not shown a clear causal link [4]. Patients with severe abdominal pain that radiates to the back should stop the medication and seek evaluation immediately.

Who Qualifies for Semaglutide?

Per FDA approval for chronic weight management, you qualify if you have:

• A BMI of 30 or higher (obesity), OR
• A BMI of 27 or higher with at least one weight-related condition (hypertension, type 2 diabetes, dyslipidemia, sleep apnea, cardiovascular disease)

Contraindications include:

• Personal or family history of medullary thyroid cancer
• Multiple endocrine neoplasia syndrome type 2 (MEN2)
• Pregnancy or breastfeeding
• Current or recent pancreatitis
• Active gallbladder disease (relative, discuss with provider)

Compounded Semaglutide vs Brand-Name

The FDA permits compounded versions of semaglutide when there are documented shortages of the brand-name drug. Compounded semaglutide is prepared by 503A or 503B licensed pharmacies and is bioequivalent at the active-ingredient level. The advantages are typically faster availability and significantly lower cost. Wegovy retails around $1,300 per month without insurance coverage, while compounded versions through telehealth platforms run $200 to $400 monthly.

What you should verify: that the pharmacy is properly licensed (503A for patient-specific compounds, 503B for outsourcing facilities), that the active pharmaceutical ingredient is sourced from a legitimate FDA-registered facility, and that you are receiving physician supervision throughout.

The Long-Term Question: What Happens When You Stop?

This is the most honest concern about GLP-1 therapy. The STEP 4 trial extension showed that patients who stopped semaglutide regained roughly two-thirds of the weight they had lost within a year [5]. The drug works by suppressing appetite and food cravings. When you stop, those signals return.

The clinical implication is that semaglutide should be thought of as a chronic medication, similar to a blood pressure or cholesterol drug. The condition (obesity) does not graduate. It is managed.

Some patients do successfully transition to maintenance doses (e.g., 1.0 mg every two weeks) or stop the medication while keeping the weight off through sustained behavioral changes. But the default expectation should be ongoing therapy.

What to Ask Your Provider

• Am I medically a candidate based on my BMI and comorbidities?
• What is the dose escalation plan if I do not tolerate the standard schedule?
• How often will we monitor weight, blood work, and side effects?
• What is the plan if I plateau?
• Is the pharmacy compounding this licensed and FDA-registered?
• What does my long-term maintenance look like?

Bottom Line

Semaglutide is the most effective non-surgical weight loss therapy currently available. It is not magic. It works by modifying the hormonal signals that drive eating, and the weight loss requires consistent weekly dosing combined with reasonable lifestyle support. For patients who qualify, the data is unambiguous: this is the therapy that finally moves the needle on obesity.

If you are considering it, work with a physician who treats GLP-1 weight management as a long-term medical condition rather than a short-term aesthetic intervention. The patients who do best understand that this is a tool, not a cure, and they pair the medication with the kind of lifestyle support that makes the loss durable.